Post by prcgorman2 on Dec 3, 2023 14:23:57 GMT -5
He also proved excellent at climbing the corporate ladder. I find it amusing you call it “brave” that he accepted his positions at MNKD. He promised thousands of weekly Afrezza scripts in short order. “I always deliver.” Parties with Dame Dash, infield passes to Indy Car races, heady stuff for a pharmacist. He’s been rewarded for his bravery with millions of shares and dollars, seems like a good deal for him. Despite the unforced errors and lack of delivery of shareholder value, he still has the opportunity to make good on his promises and I’m pulling for him as long as he remains.
Would you voluntarily leave a good senior executive position at a well-established company to take on re-launch of a drug with an average success rate estimated at 35%? And on which the very existence of the company relied? Brave is an understatement.
Have you paid attention to the perks of CEOs of companies with a billion dollar capitalization? Considering they barely have a life outside their job, I don't typically see a lot of sniping. And, as I've said many times, show me objective information showing MannKind executive compensation is simply out of range for the type and size of company that MannKind is, and we'll be closer aligned. (You did point to a survey which did indicate they may be at the top end of an appropriate range, so I'll give you that.)